Please assess the completion status of the following clinical trial:

Trial Title: Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age younger than 18 years~* Newborns (preterm or not) in neonatal intensive care~* Infants, children, and adolescents in pediatric intensive care~* Clinically suspected or microbiologically proven sepsis that might be associated with ventilator-associated pneumonia or otherwise associated with health care~* Need for antibiotic treatment by piperacillin-tazobactam, ceftazidime, or meropenem of intermittent administration~* Informed consent form signed by parents/guardian~* Informed consent form signed by patients old enough to understand.~Exclusion Criteria:~* Process for active limitation of treatment underway~* Suspected or known hypersensitivity to studied beta-lactams~* Renal failure, defined as serum creatinine \> 1.5 mg/dl or urine production \< 0.3 ml/kg for 24 h or anuria for 12 h.~* Co-administration of two β-lactam antibiotics~* Cystic fibrosis~* No national health insurance coverage in French center~* Family unable to understand study-related information due to language or other communication issues~* No consent obtained

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- pharmacokinetic device (Type: EXPERIMENTAL): MON4STRAT system

Based on this trial design, predict the completion outcome and termination type (if applicable).